|
|
 |
|
Viewing report
|
|
|
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
Bioseeker, Aug 2006, Pages: 305
In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Protein Kinase Inhibitors (PKI), Antibodies and Vaccines in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 300+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
The number of protein kinase inhibitor drugs has risen sharply, as the number of targets. The fiercest competition in PKI drug development is found in breast, lung, leukemia, prostate, and colorectal cancer. Several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.
The perfect date between Gleevec and Chronic Myeloid Leukemia (CML) will however be hard to achieve by other inhibitors currently in development, because of CMLïs strong link to a sole pathogenic event - the Philadelphia chromosome. Thus, it is expected that multiple inhibitors may have to be used together to effect higher cure rates in cancers with multiple genetic abnormalities.
Protein Kinase Inhibitors Highlights:
- Drugs according to protein kinase target; Dual or multiple kinase inhibitor analysis
- Targets according to indication
- Competitive landscape assessment
- Protein kinase inhibitors on market
- Thorough review of the seven largest cancer indications in the field of protein kinase inhibitors
- Among the targeted therapies for cancer, immunotherapy is probably the most versatile treatment strategy for the eradication of tumors, metastatic spread or not. Main strategies of cancer immunotherapy aim at exploiting the therapeutic potential of tumor-specific antibodies and cellular immune effector mechanisms (vaccines).
Immunotherapy Highlights:
- In-depth competitive landscape assessment of the cancer immunotherapy market place; - Including more than 200 immunotherapy drugs and pharmaceutical companies
- Thorough review of tumor antigen discovery, immunomodulating strategies and adjuvants
- Thorough review of antibody and vaccine delivery and technologies surrounding it - The next generation
- Progress analysis of six major cancer vaccine indications and late stage antibody development projects, including players, drugs, clinical progress and pitfalls
Customers who bought this item also bought
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
Breast Cancer - Therapeutic And Competitive Insights
Drug Delivery in Cancer - Technologies, Markets and Companies
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
Prostate and Breast Cancer- New Treatments & Developmental Progress
Strategic Outlook On Protein Kinase Inhibitors in Oncology
Analytical Tool - Protein Kinase Inhibitors in Oncology
|
|
|
|
